Novo Nordisk stock trades at EUR 34.05 with a 9.7 P/ E ratio
Published on 10/09/2026 at 15:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Novo Nordisk stock was trading at EUR 34.05 at Lang & Schwarz on October 9, 2026, plus 0.09 percent versus EUR 34.02.
- The finance quote showed a 9.7 P/E ratio and market capitalization of USD 169.5 billion as of October 8, 2026.
- Novo Nordisk is scheduled to report its next results on November 4, 2026.
- The comparison block places Novo Nordisk alongside Eli Lilly and Pfizer using dated market figures.
Novo Nordisk (DK0062498333) was trading at EUR 34.05 at Lang & Schwarz on October 9, 2026 at 3:15 p.m. CEST, up 0.09 percent versus the EUR 34.02 prior close. The bid was EUR 34.05 and the ask EUR 34.06, leaving the spread at EUR 0.01.
Price stays near the daily quote
The Lang & Schwarz price was EUR 34.05 at the stated time, while the prior close was EUR 34.02 on October 8, 2026. The small move keeps the report centered on placement, valuation and scheduled dates rather than a directional market call.
The NVO quote in US dollars stood at USD 38.18 on October 8, 2026. Its 52-week range was USD 35.12 to USD 64.16, and the same quote showed volume of 11,432,838 shares against an average of 12,639,184.
Valuation and the next date
The quote carried a P/E ratio of 9.7 and a dividend yield of 5.00 percent as of October 8, 2026. Market capitalization was USD 169.5 billion on the same date, giving the valuation figures a clear time reference.
MarketScreener reported that Morgan Stanley rated Novo Nordisk Underweight on September 11, 2026 while keeping its DKK 250.00 price target unchanged. The report also listed a DKK 307.56 average target and a Hold consensus from 25 analysts.
Gekko lists November 4, 2026 as Novo Nordisk's next earnings date, with consensus estimates of USD 0.75 for earnings per share and USD 11.09 billion in revenue.
Comparison with peers
Novo Nordisk (Lang & Schwarz, EUR): plus 0.09 percent, P/E 9.7, market capitalization USD 169.5 billion
Eli Lilly (NYSE, USD): minus 1.58 percent, P/E 39.3, market capitalization USD 1,101.8 billion
Pfizer (NYSE, USD): minus 0.64 percent, P/E 36.8, market capitalization USD 158.6 billion
Home listing and market view
De Belegger identifies Nasdaq Copenhagen as Novo Nordisk's home listing and Frankfurt as a secondary euro listing. The company operates in pharmaceuticals and reports in Danish kroner.
The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: NOVO-B.CO
- Primary exchange: Nasdaq Copenhagen
- Price Lang & Schwarz (as of October 9, 2026, 3:15 p.m. CEST): EUR 34.05
- Change versus prior close: plus 0.09 percent
- Prior close Lang & Schwarz (October 8, 2026): EUR 34.02
- Market capitalization: USD 169.5 billion (as of October 8, 2026)
- 52-week range: USD 35.12-64.16 (as of October 8, 2026)
- Sector / Industry: Pharmaceuticals
- Index membership: OMX Copenhagen 20
- Next earnings date: November 4, 2026
Market context: Current market reports.
